SK pharmteco Acquires Controlling Interest in Center for Breakthrough Medicines
September 19, 2023
SK pharmteco is acquiring a controlling interest in cell and gene therapy CDMO Center for Breakthrough Medicines (CBM), integrating CBM with its Paris-based Yposkesi to create a global cell & gene therapy business unit. The deal expands SK pharmteco's technical capabilities, production capacity, and U.S./European footprint in advanced biologics manufacturing.
- Buyers
- SK pharmteco
- Targets
- Center for Breakthrough Medicines
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.